Schedule 13G ownership disclosure

SILENCE THERAPEUTICS PLC

Ordinary share, nominal value 0.05 GBP per share · CUSIP: 82686Q101

Event date: 2026-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Invus Public Equities, L.P.

    Shares: 7,591,233.00 · Class: 4.1%

  • Invus Public Equities Advisors, LLC

    Shares: 7,591,233.00 · Class: 4.1%

  • Invus Global Management, LLC

    Shares: 7,591,233.00 · Class: 4.1%

  • Siren, L.L.C.

    Shares: 7,591,233.00 · Class: 4.1%

  • Avicenna Life Sci Master Fund LP

    Shares: 1,072,368.00 · Class: 0.6%

  • Avicenna Life Sci Master GP LLC

    Shares: 1,072,368.00 · Class: 0.6%

  • Ulys, L.L.C.

    Shares: 1,072,368.00 · Class: 0.6%

  • Raymond Debbane

    Shares: 8,663,601.00 · Class: 4.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002005369-26-000060
Form type
SCHEDULE 13G/A
Filer
Invus Global Management, LLC
CIK
CIK 2005369
Filed
Nov 12, 2026
Reporting period
Sep 30, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub